"Roche Holding AG has decided not to pursue a patent application for its breast cancer drug Herceptin in India, the Swiss company said on Friday, as Western drugmakers come under pressure over high prices in the fast-growing market.
The Kolkata Patent Office said earlier this month that it had dismissed certain patent applications filed by Roche, because the company had failed to submit the applications for Herceptin correctly.
"Roche has come to the conclusion not to pursue Indian Patent No. 205534 (the secondary patent) and the related divisional applications," a Roche spokesman said in an emailed statement. "This decision takes into account the strength of the particular rights and the IP (intellectual property) environment in India in general.
Western pharmaceutical companies are keen to tap into India's $13 billion drug market, but there are concerns about the level of protection for intellectual property in the country, where generic medicines account for more than 90 percent of drug sales."
Via Susan Zager